Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 4177

1.

Comparison between hypersensitivity reactions to cycles of modified FOLFOX6 and XELOX therapies in patients with colorectal cancer.

Ohta H, Hayashi T, Murai S, Shiouchi H, Ando Y, Kumazawa S, Ito K, Ikeda Y, Matsuoka H, Maeda K, Kawada K, Yasuda K, Yamada S.

Cancer Chemother Pharmacol. 2017 May;79(5):1021-1029. doi: 10.1007/s00280-017-3294-9. Epub 2017 Apr 8.

2.

Nanosomal Docetaxel Lipid Suspension: A Guide to Its Use in Cancer.

McKeage K.

Clin Drug Investig. 2017 Apr;37(4):405-410. doi: 10.1007/s40261-017-0510-7.

PMID:
28255844
3.

The Impact of Early Dermatologic Events in the Survival of Patients with Hepatocellular Carcinoma Treated with Sorafenib.

Branco F, Alencar RS, Volt F, Sartori G, Dode A, Kikuchi L, Tani CM, Chagas AL, Pfiffer T, Hoff P, Carrilho FJ, Mattos AA.

Ann Hepatol. 2017 March-April;16(2):263-268. doi: 10.5604/16652681.1231585.

4.
5.

The Effects of Prolonged Infusion on Reducing Oxaliplatin Hypersensitivity Reactions.

Zhang X, Zhao Y, Zheng Y, Dong Y.

J Investig Allergol Clin Immunol. 2017;27(1):65-66. doi: 10.18176/jiaci.0119. No abstract available.

6.

Risk of cumulative toxicity after complete melanoma response with pembrolizumab.

Hsieh AH, Faithfull S, Brown MP.

BMJ Case Rep. 2017 Feb 1;2017. pii: bcr2016218308. doi: 10.1136/bcr-2016-218308.

PMID:
28148549
7.

Association of IL4, IL13, and IL4R polymorphisms with gastrointestinal cancer risk: A meta-analysis.

Cho YA, Kim J.

J Epidemiol. 2017 May;27(5):215-220. doi: 10.1016/j.je.2016.06.002. Epub 2017 Jan 5.

8.

Lichenoid Dermatologic Toxicity From Immune Checkpoint Blockade Therapy: A Detailed Examination of the Clinicopathologic Features.

Tetzlaff MT, Nagarajan P, Chon S, Huen A, Diab A, Omar P, Aung PP, Torres-Cabala CA, Mays SR, Prieto VG, Curry JL.

Am J Dermatopathol. 2017 Feb;39(2):121-129. doi: 10.1097/DAD.0000000000000688.

PMID:
28134729
9.

Cutaneous Reactions to Targeted Therapy.

Lee JJ, Kroshinsky D, Hoang MP.

Am J Dermatopathol. 2017 Feb;39(2):67-82. doi: 10.1097/DAD.0000000000000504. Review.

PMID:
28134724
10.

Management of acute skin toxicity with Hypericum perforatum and neem oil during platinum-based concurrent chemo-radiation in head and neck cancer patients.

Franco P, Rampino M, Ostellino O, Schena M, Pecorari G, Garzino Demo P, Fasolis M, Arcadipane F, Martini S, Cavallin C, Airoldi M, Ricardi U.

Med Oncol. 2017 Feb;34(2):30. doi: 10.1007/s12032-017-0886-5. Epub 2017 Jan 18.

11.

Loss of CUL4A expression is underlying cisplatin hypersensitivity in colorectal carcinoma cells with acquired trabectedin resistance.

Englinger B, Mair M, Miklos W, Pirker C, Mohr T, van Schoonhoven S, Lötsch D, Körner W, Ferk F, Knasmüller S, Heffeter P, Keppler BK, Grusch M, Berger W.

Br J Cancer. 2017 Feb 14;116(4):489-500. doi: 10.1038/bjc.2016.449. Epub 2017 Jan 17.

PMID:
28095394
12.

Cisplatin can be safely administered to ovarian cancer patients with hypersensitivity to carboplatin.

Bergamini A, Pisano C, Di Napoli M, Arenare L, Della Pepa C, Tambaro R, Facchini G, Gargiulo P, Rossetti S, Mangili G, Pignata S, Cecere SC.

Gynecol Oncol. 2017 Jan;144(1):72-76. doi: 10.1016/j.ygyno.2016.10.023. Epub 2016 Oct 27.

PMID:
28094039
13.

Quincke's edema and hypersensitivity pneumonitis induced by lenalidomide for multiple myeloma.

Hatsuse M, Odaira E, Fuchida SI, Okano A, Murakami S, Shimazaki C.

Rinsho Ketsueki. 2016;57(12):2502-2506. doi: 10.11406/rinketsu.57.2502. Review.

PMID:
28090017
14.

Histologic Assessment of Lichenoid Dermatitis Observed in Patients With Advanced Malignancies on Antiprogramed Cell Death-1 (anti-PD-1) Therapy With or Without Ipilimumab.

Chou S, Hwang SJ, Carlos G, Wakade D, Fernandez-Penas P.

Am J Dermatopathol. 2017 Jan;39(1):23-27. doi: 10.1097/DAD.0000000000000587.

PMID:
28045749
15.

Idelalisib-induced colitis and skin eruption mimicking graft-versus-host disease.

Hammami MB, Al-Taee A, Meeks M, Fesler M, Hurley MY, Cao D, Lai JP.

Clin J Gastroenterol. 2017 Apr;10(2):142-146. doi: 10.1007/s12328-016-0707-y. Epub 2016 Dec 26.

PMID:
28025783
16.

A Difference in the Incidences of Hypersensitivity Reactions to Original and Generic Taxanes.

Ratanajarusiri T, Sriuranpong V, Sitthideatphaiboon P, Poovoravan N, Vinayanuwat C, Parinyanitikul N, Angspatt P, Thawinwisan W, Tanasanvimon S.

Chemotherapy. 2017;62(2):134-139. doi: 10.1159/000450748. Epub 2016 Dec 20.

PMID:
27997900
18.

[Clinical analysis of hypersensitivity reaction of platinum in ovarian cancer and cervical cancer patients].

Li L, Wu M, Yang JX, Wan XR, Huang HF, Pan LY, Shen K, Lang JH, Xiang Y.

Zhonghua Fu Chan Ke Za Zhi. 2016 Nov 25;51(11):825-831. doi: 10.3760/cma.j.issn.0529-567X.2016.11.005. Chinese.

PMID:
27916065
19.

Optimizing combination dabrafenib and trametinib therapy in BRAF mutation-positive advanced melanoma patients: Guidelines from Australian melanoma medical oncologists.

Atkinson V, Long GV, Menzies AM, McArthur G, Carlino MS, Millward M, Roberts-Thomson R, Brady B, Kefford R, Haydon A, Cebon J.

Asia Pac J Clin Oncol. 2016 Dec;12 Suppl 7:5-12. doi: 10.1111/ajco.12656.

PMID:
27905182
20.

Toxische Hautreaktionen und Unterstützungsbedarf von KrebspatientInnen im Zuge einer EGFR-Antikörpertherapie.

Matzka M, Stöhr D, Colditz A, Köck-Hódi S, Koller M, Mayer H.

Pflege. 2017 Jan;30(1):9-17. doi: 10.1024/1012-5302/a000521. Epub 2016 Nov 30. German. No abstract available.

PMID:
27901405

Supplemental Content

Loading ...
Support Center